STU:7ZT (Sweden)
Â
Ordinary Shares - Class B
€
0.33
-0.0040 (-1.2%)
Apr 1
What is a stock summary page? Click here for an overview.
Business Description
Hamlet BioPharma AB publ
ISIN : SE0015661152
Share Class Description:
STU:7ZT: Ordinary Shares - Class BCompare
Compare
Traded in other countries / regions
HAMLET B.Sweden7ZT.Germany IPO Date
2024-06-04Description
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -40.3 | |||||
3-Year EPS without NRI Growth Rate | -49.8 | |||||
3-Year FCF Growth Rate | -57.8 | |||||
3-Year Book Growth Rate | 145.3 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.04 | |||||
9-Day RSI | 48.06 | |||||
14-Day RSI | 51.15 | |||||
3-1 Month Momentum % | 22.64 | |||||
6-1 Month Momentum % | 9.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.85 | |||||
Quick Ratio | 6.85 | |||||
Cash Ratio | 5.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.4 | |||||
Shareholder Yield % | -3.7 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -77.45 | |||||
ROA % | -71.12 | |||||
ROIC % | -108.54 | |||||
3-Year ROIIC % | -99.37 | |||||
ROC (Joel Greenblatt) % | -9361.01 | |||||
ROCE % | -77.34 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 10.91 | |||||
Price-to-Tangible-Book | 32.8 | |||||
EV-to-EBIT | -13.52 | |||||
EV-to-EBITDA | -17.02 | |||||
EV-to-FCF | -16.74 | |||||
Price-to-Net-Current-Asset-Value | 32.8 | |||||
Price-to-Net-Cash | 32.8 | |||||
Earnings Yield (Greenblatt) % | -7.4 | |||||
FCF Yield % | -6.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hamlet BioPharma AB publ Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.024 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | - | ||
14-Day RSI | 51.15 | ||
14-Day ATR (€) | 0.017729 | ||
20-Day SMA (€) | 0.33675 | ||
12-1 Month Momentum % | - | ||
52-Week Range (€) | 0.1985 - 0.391 | ||
Shares Outstanding (Mil) | 177.69 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hamlet BioPharma AB publ Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hamlet BioPharma AB publ Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Hamlet BioPharma AB publ Frequently Asked Questions
What is Hamlet BioPharma AB publ(STU:7ZT)'s stock price today?
The current price of STU:7ZT is €0.33. The 52 week high of STU:7ZT is €0.39 and 52 week low is €0.20.
When is next earnings date of Hamlet BioPharma AB publ(STU:7ZT)?
The next earnings date of Hamlet BioPharma AB publ(STU:7ZT) is 2025-05-22.
Does Hamlet BioPharma AB publ(STU:7ZT) pay dividends? If so, how much?
Hamlet BioPharma AB publ(STU:7ZT) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |